Degradation Pathways of a Corticotropin-Releasing Factor Antagonist in Solution and Solid States

被引:3
|
作者
Badawy, S. [1 ]
Hussain, M. [1 ]
Zhao, F. [1 ]
Ye, Q. [1 ]
Huang, Y. [1 ]
Palaniswamy, V. [1 ]
机构
[1] Bristol Myers Squibb Co, Pharmaceut Dev, New Brunswick, NJ 08903 USA
关键词
chemical stability; stability; solid state stability; stabilization; solid dosage form; HYDROLYSIS;
D O I
10.1002/jps.21637
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Stability of the 1,3,5-triazine derivative (1), a corticotropin-releasing factor inhibitor, was studied in acidic solutions and in solid formulations. Degradant structures were elucidated using liquid chromatography/mass spectrometry (LC/MS) and nuclear magnetic resonance (NMR). Compound I was found to undergo hydrolysis via two pathways. Pathway 1 involves three hydrolysis steps of the triazine ring. Pathway 2 proceeds through hydroxy substitution of the amino group on the triazine ring followed by its hydrolysis, eventually resulting in the formation of the same degradant as pathway 1. Stability of 1 in the tablets was dependent on the manufacturing process and degradation appeared to proceed more rapidly in amorphous regions created during processing. Pathways 1 and 2 were observed in the tablets and degradation rate was enhanced at. high humidity condition. In addition to pathways I and 2, degradation in the tablet formulations was found to proceed through a third pathway involving nucleophilic displacement of the ether methoxy group by the triazine N-3. The resulting imidazolidinium intermediate was found to undergo a series of hydrolytic steps finally leading to the same end degradant as pathways 1 and 2. This intermediate was observed at a lower concentration in the tablet at the high humidity conditions and at very low concentrations in acidic solutions. (C) 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2636-2647, 2009
引用
收藏
页码:2636 / 2647
页数:12
相关论文
共 50 条
  • [1] CORTICOTROPIN-RELEASING FACTOR
    YASUDA, N
    GREER, MA
    AIZAWA, T
    ENDOCRINE REVIEWS, 1982, 3 (02) : 123 - 140
  • [2] CORTICOTROPIN-RELEASING FACTOR
    JENNES, L
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 597 : 231 - 238
  • [3] THE CORTICOTROPIN-RELEASING FACTOR
    CONTEDEVOLX, B
    OLIVER, C
    REY, M
    GUILLAUME, V
    CASTANAS, E
    GIRAUD, P
    BOUDOURESQUE, F
    GRINO, M
    PRESSE MEDICALE, 1985, 14 (13): : 737 - 741
  • [4] CORTICOTROPIN-RELEASING FACTOR
    DUNTAS, L
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1988, 113 (19) : 794 - 794
  • [5] HUMAN PLACENTAL CORTICOTROPIN-RELEASING FACTOR IS IDENTICAL TO HYPOTHALAMIC CORTICOTROPIN-RELEASING FACTOR
    STALLA, GK
    BOST, H
    KALIEBE, T
    HUBER, M
    STALLA, J
    PFEIFFER, D
    VONWERDER, K
    MULLER, OA
    ACTA ENDOCRINOLOGICA, 1986, 111 : 169 - 169
  • [6] CHARACTERIZATION OF A NOVEL AND POTENT CORTICOTROPIN-RELEASING FACTOR ANTAGONIST IN RATS
    MENZAGHI, F
    HOWARD, RL
    HEINRICHS, SC
    VALE, W
    RIVIER, J
    KOOB, GF
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1994, 269 (02): : 564 - 572
  • [7] Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist
    Keller, C
    Bruelisauer, A
    Lemaire, M
    Enz, A
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (02) : 173 - 176
  • [8] Progress in corticotropin-releasing factor-1 antagonist development
    Zorrilla, Eric P.
    Koob, George F.
    DRUG DISCOVERY TODAY, 2010, 15 (9-10) : 371 - 383
  • [9] SAFETY OF CORTICOTROPIN-RELEASING FACTOR
    SCHULTE, HM
    CHROUSOS, GP
    CHATTERJI, DC
    GOLD, PW
    OLDFIELD, EH
    LORIAUX, DL
    LANCET, 1983, 1 (8335): : 1222 - 1222
  • [10] CORTICOTROPIN-RELEASING FACTOR AND BEHAVIOR
    KOOB, GF
    BLOOM, FE
    FEDERATION PROCEEDINGS, 1985, 44 (01) : 259 - 263